[go: up one dir, main page]

ATE395061T1 - Topische zusammensetzungen zur transdermalen gabe von niacin prodrugs sowie verfahren zur behandlung von hyperlipidämie - Google Patents

Topische zusammensetzungen zur transdermalen gabe von niacin prodrugs sowie verfahren zur behandlung von hyperlipidämie

Info

Publication number
ATE395061T1
ATE395061T1 AT01930535T AT01930535T ATE395061T1 AT E395061 T1 ATE395061 T1 AT E395061T1 AT 01930535 T AT01930535 T AT 01930535T AT 01930535 T AT01930535 T AT 01930535T AT E395061 T1 ATE395061 T1 AT E395061T1
Authority
AT
Austria
Prior art keywords
methods
transdermal administration
topical compositions
treating hyperlipidemia
niacin
Prior art date
Application number
AT01930535T
Other languages
English (en)
Inventor
Myron Jacobson
Hyuntae Kim
Moonsun Kim
Elaine Jacobson
Jaber Qasem
Original Assignee
Niadyne Corp
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22730106&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE395061(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Niadyne Corp, Univ Kentucky Res Found filed Critical Niadyne Corp
Application granted granted Critical
Publication of ATE395061T1 publication Critical patent/ATE395061T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT01930535T 2000-04-14 2001-04-16 Topische zusammensetzungen zur transdermalen gabe von niacin prodrugs sowie verfahren zur behandlung von hyperlipidämie ATE395061T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19762100P 2000-04-14 2000-04-14

Publications (1)

Publication Number Publication Date
ATE395061T1 true ATE395061T1 (de) 2008-05-15

Family

ID=22730106

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01930535T ATE395061T1 (de) 2000-04-14 2001-04-16 Topische zusammensetzungen zur transdermalen gabe von niacin prodrugs sowie verfahren zur behandlung von hyperlipidämie

Country Status (14)

Country Link
US (1) US6677361B2 (de)
EP (1) EP1274429B1 (de)
JP (1) JP4156841B2 (de)
CN (1) CN1430513B (de)
AT (1) ATE395061T1 (de)
AU (2) AU5706301A (de)
CA (1) CA2441461C (de)
DE (1) DE60134002D1 (de)
DK (1) DK1274429T3 (de)
ES (1) ES2302732T3 (de)
HK (1) HK1053607A1 (de)
MX (1) MXPA02010184A (de)
PT (1) PT1274429E (de)
WO (1) WO2001078727A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6464992B2 (en) * 2000-04-14 2002-10-15 University Of Kentucky Research Foundation Topical micronutrient delivery system and uses thereof
US20040081672A1 (en) * 2002-10-25 2004-04-29 Gupta Shyam K. Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging
US20040191278A1 (en) * 2003-03-31 2004-09-30 Christensen Flemming Kjaergaar Topical agent for application to the skin prior to luminous treatment
US20040254202A1 (en) * 2003-06-13 2004-12-16 The Procter & Gamble Company Method of promoting sleep using topical administration of vasoactive agents
US20050267091A1 (en) * 2004-05-25 2005-12-01 Roger Berlin Compositions containing policosanol and niacin and/or niacin derivatives and their pharmaceutical uses
CN101742916B (zh) * 2007-02-28 2015-08-19 肯塔基大学研究基金会 减轻视黄酸治疗副作用和/或改进疗效而不干扰疗效的方法
US20100292280A1 (en) * 2007-04-15 2010-11-18 Oron Zachar Anti-pyretic vasodilators
CN102532114B (zh) * 2011-12-19 2016-08-03 中山大学 烟酸衍生物,其制备方法及其药物组合物
WO2014179845A1 (en) 2013-05-09 2014-11-13 Zeenar Enterprises Pty Ltd Niacin formulation
AU2015270090A1 (en) 2014-06-06 2016-12-22 Glaxosmithkline Intellectual Property (No.2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
JP2020532295A (ja) * 2017-08-31 2020-11-12 ロンザ，エルエルシー 健康促進組成物およびサプリメントの使用方法
EP3727315B1 (de) 2017-12-18 2021-10-13 Unilever Global IP Limited Topische zusammensetzung enthaltend n-cyclopropylnicotinamid
WO2019121548A1 (en) * 2017-12-18 2019-06-27 Unilever N.V. A topical composition based on niacinamide derivative
WO2020089236A1 (en) 2018-11-02 2020-05-07 Unilever Plc Bioenergetic nicotinic acid glycerol esters, compositions and methods of using same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1046055B (de) * 1956-06-18 1958-12-11 Ernst Schneider Dipl Chem Dr Verfahren zur Herstellung eines Esters mehrfach ungesaettigter hoehermolekularer Fettsaeuren
DE3570598D1 (en) * 1984-11-15 1989-07-06 Nitto Denko Corp Composition for percutaneous administration
GB2210789A (en) * 1987-10-10 1989-06-21 Morrison Dr Ian Donald Topical application for skin care
EP0346490B1 (de) * 1987-12-24 1993-04-07 Fujisawa Pharmaceutical Co., Ltd. Wirkstoff zur stimulierung des haarwuchses
EP0643965B1 (de) * 1993-09-20 2013-05-08 Abbott Laboratories Nicotinsäure enthaltende Zusammensetzungen zur Behandlung der Hyperlipidämie
US5496827A (en) * 1994-07-15 1996-03-05 Patrick; Jay Compositions for the transdermal delivery of nutrients
WO1996032942A1 (en) * 1995-04-19 1996-10-24 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
ES2225879T3 (es) * 1995-05-01 2005-03-16 Scarista Limited Esteres de acido nicotinico y composiciones farmaceuticas que los contienen.
GB9610971D0 (en) * 1996-05-29 1996-07-31 Scotia Holdings Plc A diagnostic test for use in schizophrenia
US20040102358A1 (en) * 1997-05-19 2004-05-27 Scivoletto Rosemarie Composition for treating skin conditions
IL143112A0 (en) * 1998-12-01 2002-04-21 Univ Kentucky Res Found A method for enhancing protective cellular responses to genotoxic stress in skin
US6464992B2 (en) * 2000-04-14 2002-10-15 University Of Kentucky Research Foundation Topical micronutrient delivery system and uses thereof

Also Published As

Publication number Publication date
CN1430513B (zh) 2010-12-08
US20010049382A1 (en) 2001-12-06
DE60134002D1 (de) 2008-06-26
ES2302732T3 (es) 2008-08-01
WO2001078727A1 (en) 2001-10-25
AU2001257063B2 (en) 2005-04-28
AU5706301A (en) 2001-10-30
PT1274429E (pt) 2008-06-17
CA2441461A1 (en) 2001-10-25
DK1274429T3 (da) 2008-08-25
CN1430513A (zh) 2003-07-16
JP4156841B2 (ja) 2008-09-24
EP1274429A4 (de) 2006-03-01
MXPA02010184A (es) 2004-08-19
WO2001078727A8 (en) 2003-11-27
CA2441461C (en) 2007-07-10
EP1274429A1 (de) 2003-01-15
US6677361B2 (en) 2004-01-13
EP1274429B1 (de) 2008-05-14
JP2004500428A (ja) 2004-01-08
HK1053607A1 (en) 2003-10-31

Similar Documents

Publication Publication Date Title
ATE395061T1 (de) Topische zusammensetzungen zur transdermalen gabe von niacin prodrugs sowie verfahren zur behandlung von hyperlipidämie
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
PT1239849E (pt) Formulacoes farmaceuticas que compreendem resveratrol e a sua utilizacao
NO20025263L (no) Topisk sammensetning for behandlingen av psoriasis og beslektede hud-lidelser
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
ATE361084T1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
DK1259240T3 (da) Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme
ES2136252T3 (es) Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa.
NO20071798L (no) Dermalt pafore formuleringer for behandling av hudsykdommer i dyr
BR0308957A (pt) Composto, composição farmacêutica, método para o tratamento de uma inflamação ou de uma desordem associada a uma inflamação em um paciente, uso dos compostos e processo para sua preparação
DE60142632D1 (de) Heilung von wunden
HRP20050633A2 (en) Formulation and methods for the treatment of thrombocythemia
PA8525801A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
BR0007452A (pt) Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação
DK1638582T3 (da) Anvendelse af hyaluronsyre til fremstilling af kompositioner til behandling af tilbagevendende after
DE69927260D1 (de) Topische pharmazeutische zusammensetzung zur behandlung von haut- oder zirkulatorischen krankheiten auf inflammatorischer, immun-, proliferativer oder degenerativer basis
IL190850A (en) Use of Artemisinin and Derivatives to Prepare a Pharmacist and Insulin Composition Containing Local Compositions Containing Them
WO2004030623A3 (en) Nitroxide radioprotector formulations and methods of use
DK1594456T3 (da) Anvendelse af en sammensætning indeholdende vitamin K1-oxid eller et derivat deraf til behandling og/eller forebyggelse af dermatologiske læsioner hos pattedyr
SE0203817D0 (sv) New composition
IT1265647B1 (it) Composizione farmaceutiche topiche per le allergie respiratorie
ATE241640T1 (de) Fusidinsäure-derivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1274429

Country of ref document: EP